10X Genomics Inc reports results for the quarter ended in January 1 - Earnings Summary

10x Genomics

30/10/2024 02:49

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 30 cents​​ per share for the quarter ended January 1, higher
than the same quarter last year, when the company reported EPS
of -79 cents.  The mean expectation of nineteen analysts for the
quarter was for a loss of 34 cents per share. Wall Street
expected results to range from -57 cents to -27 cents per share.
    * Revenue fell 1.3% to $151.65 million from a year ago;
analysts
expected $158.63 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 30
cents​.
    * The company reported a quarterly loss of $35.75 million.
    * 10X Genomics Inc shares had fallen by 29.8% this
quarter and
lost 71.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.2%
in the last three months.​ 
    * In the last 30 days, five analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is 22.50 
This summary was machine generated from LSEG data October 30 at
02:49 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.34          -0.30          Beat
 Jun. 30 2024      -0.48          -0.32          Beat
 Mar. 31 2024      -0.50          -0.50          Met
 Dec. 31 2023      -0.36          -0.41          Missed